First monoclonal antibody for CD112R detection in IHC/FFPE tissue out now! Validated for Fluorescence Multiplex IHC with unique FOXP3 antibody.

test our

ANTIBODIES

CD112R antibody

CD112R

The unique clone R12 is ideally suited for multiplexed IHC studies of CD112R expression in human tissue specimen.

TIGIT antibody

TIGIT

Clone TG1 is simply the best anti-TIGIT antibody available so far – as proven by beta-tests from different labs.

FOXP3 antibody

FOXP3

The new clone FX3 has been characterized on hundreds of tissues and validated for multiplex fluorescence IHC.

CD8

Clone TC8 displays highest signal-to-noise contrast and has been validated for detection of CD8+ TILs in multiplex assays.

CD73

Clone KK3 is highly efficient in detection of CD73-adenosine in normal and tumor FFPE tissue.

LAG3

Coming soon – This clone has been validated on a high range of tissues to document unparalleled quality.

anti-PSA antibody

PSA

Clone HAM18 has been tested on >20.000 tissues and is the best characterized anti-PSA antibody.

p16

Clone JAP16 is outstanding and superior to competitors as proven by beta-tests from different labs.

We are always happy to discuss your needs!

look

WHAT WE DO

ONCOdianova is an antibody manufacturing network. The purpose is to manufacture excellent antibodies with optimized signal-to-noise ratio. Such optimized antibodies are especially needed in multicolor fluorescence based immunohistochemistry if many different antibodies are simultaneously analyzed. The mission of ONCOdianova is to develop a portfolio of “best in class antibodies” for proteins that are potentially relevant for triggering treatment decisions or for diagnostic pathology.

Develop

Our idea is to integrate immunohistochemistry as early as possible in the hybridoma screening procedure and thereby expand the classical ELISA screen by histopathological expertise at an early stage of FFPE antibody development.

Validate

We use our strong network for histopathological validation of new targets in human tissues. This expands our expertise to develop new test systems for novel targets. For cancer immunology targets we put a focus on tumor infiltrating lymphocytes.

Improve

Multiplex Assay technology develops fast and depends on the availability of reliable antibody reagents. Our vision is to provide the best cancer immunology marker antibodies for combined use to improve the understanding of patient subpopulations.

Partner

Our objective is to potentially develop multiple clones for the same target by approaching one target at diverse immunogenic sites. We are able to reference mapped epitopes and open for beta testing opportunities with pharmaceutical partners.

Menu